KZIA:NASDAQKazia Therapeutics Limited Analysis
Data as of 2026-04-13 - not real-time
$8.99
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Kazia Therapeutics is trading at $8.99, comfortably above its 20‑day SMA of 7.84 and 50‑day SMA of 7.29, while the bullish MACD (histogram +0.17) and a neutral‑to‑slightly‑overbought RSI of 60.8 suggest short‑term momentum. The stock sits near its technical resistance of 9.76 with a solid support cushion at 6.82, and a DCF‑derived fair value of $9.64 implies modest upside, reinforced by analyst price targets averaging $19.35.
Fundamentally, Kazia’s revenue base is modest (~$1.9 M) and operating margins are deeply negative (‑146%), yet the company holds a strong cash position of ~$69 M against minimal debt, providing runway for its pipeline. Volatility is extreme (30‑day ≈ 112%) and beta is high (1.62), reflecting the biotech sector’s inherent risk, compounded by a recent encouraging Phase 1b result showing a 50% tumor reduction in a triple‑negative breast cancer patient. These dynamics create a high‑risk, high‑potential profile.
Fundamentally, Kazia’s revenue base is modest (~$1.9 M) and operating margins are deeply negative (‑146%), yet the company holds a strong cash position of ~$69 M against minimal debt, providing runway for its pipeline. Volatility is extreme (30‑day ≈ 112%) and beta is high (1.62), reflecting the biotech sector’s inherent risk, compounded by a recent encouraging Phase 1b result showing a 50% tumor reduction in a triple‑negative breast cancer patient. These dynamics create a high‑risk, high‑potential profile.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 6/10
Key Factors
- Bullish MACD and price above short‑term SMAs
- Positive early trial data (50% tumor reduction)
- Support level well below current price
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- DCF fair value ($9.64) above market price
- Analyst target price (~$19.35) indicating upside
- Strong cash runway (~$69 M) with minimal debt
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Potential regulatory approvals for paxalisib in CNS cancers
- Strategic collaborations (Genentech, Simcere, etc.)
- High‑growth pipeline despite current operating losses
Key Metrics & Analysis
Financial Health
Revenue Growth312.40%
P/E Ratio-1146.7
ROE-106.90%
ROA-25.70%
Debt/Equity0.21
P/B Ratio3.2
Op. Cash Flow$-14398379
Free Cash Flow$1.1M
Industry P/E26.1
Technical Analysis
TrendNeutral
RSI60.8
Support$6.82
Resistance$9.76
MA 20$7.84
MA 50$7.29
MA 200$7.94
MACDBullish
VolumeIncreasing
Fear & Greed Index87.29
Valuation
Fair Value$9.64
Target Price$19.35
Upside/Downside115.21%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.62
Volatility112.64%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.